- Home
- LFUS vs GPCR Comparison
LFUS vs GPCR Comparison
Compare LFUS & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | LFUS | GPCR |
|---|---|---|
| Founded | 1927 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.3B |
| IPO Year | 1996 | 2023 |
Fundamental Metrics
Financial Performance| Metric | LFUS | GPCR |
|---|---|---|
| Price | $360.90 | $63.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $343.33 | $102.45 |
| AVG Volume (30 Days) | 254.6K | ★ 817.1K |
| Earning Date | 04-29-2026 | 05-29-2026 |
| Dividend Yield | ★ 0.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $757,853,000.00 | N/A |
| Revenue This Year | $14.65 | N/A |
| Revenue Next Year | $6.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $142.10 | $13.24 |
| 52 Week High | $378.45 | $94.90 |
Technical Indicators
Market Signals| Indicator | LFUS | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 33.11 |
| Support Level | $343.14 | $60.42 |
| Resistance Level | N/A | $72.00 |
| Average True Range (ATR) | 13.41 | 3.44 |
| MACD | -2.48 | -1.35 |
| Stochastic Oscillator | 51.12 | 8.15 |
Price Performance
Historical ComparisonAbout LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) for the transportation, industrial, telecommunications, and consumer electronics end markets. The company is also increasing its power semiconductor business, where it predominantly serves industrial end markets, and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.